Kornimate/medical-research-clean huggingface dataset:
the ward study for septicyte® lab to distinguish between infection-positive and infection-negative sirs

Conditions: Sepsis; SIRS

Summary: a non-interventional, prospective observational study to assess the performance of septicyte® lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative sirs

this study is evaluating a molecular diagnostic device developed to distinguish between sepsis and infection-negative sirs among critically ill patients. this study is a prospective, non-randomized, non-interventional, observational trial of patients with suspected sepsis in the medical and/or surgical wards. the study is being conducted on two preselected patient care units. all patients identified by a local screening tool undergo physician review. if the suspicion of sepsis is found to be plausible, routine and conventional diagnostic procedures, including: routine bloods, blood culture and specialized tests are conducted. blood collection for septicyte® lab and septid® is drawn within 6 hours of a positive screen - both use peripheral blood as the clinical sample. the diagnostic performance of the two experimental assays will be compared to retrospective physician diagnosis (rpd), and conventional microbiological culture. the results of septicyte® lab and septid® are not used in any clinical decision-making. this data will be used to analyze the performance of septicyte® lab according to the endpoint measures.

Eligibility criteria:
inclusion criteria: 1. 18-89 years old on the day of enrollment. 2. currently admitted to study designated medical or surgical ward 3. have a clinical suspicion of sepsis as determined by two physicians after identification by hospital screening tool. 4. screened positive for sepsis, severe sepsis or septic shock using the rise2 screening tool. 5. completed sbar handover (situation, background, assessment, recommendation) 6. sirs present as defined by the presence of two or more of the following: * temperature \> 38°c or \< 36°c * heart rate \> 90 beat/min * tachypnea \> 20/min or paco2 \< 32 mmhg * wbc count \> 12 000/mm3 or \ 10% immature neutrophils (bands) exclusion criteria: 1. consent not provided 2. patients less than 18 years of age, or 90 years of age or older. 3. patients for which a blood sample could not be taken within 24 hours of a physician first determining a clinical suspicion of sepsis. 4. patients that are not located in the designated medical or surgical ward associated with the study. 5. patients listed for "comfort measures only". 6. less than 2 sirs criteria 7. commencement of narrow spectrum directed antibiotics prior to screening.

Keywords: septicyte
a novel prognostic model of npi for risk-predicting and clinical decision-making in diffuse large b-cell lymphoma in the rituximab era

Conditions: Diffuse Large B Cell Lymphoma

Summary: the purpose of this study is to determine the predictive value of a model of nomogram prognostic index (npi) in patients with diffuse large b cell lymphoma.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of cd20+ dlbcl exclusion criteria: * primary central nervous system lymphoma * "double-hit" lymphoma
primary palliative care for patients with advanced hematologic malignancies

Conditions: Advanced Cancer

Summary: this study seeks to develop and pilot-test an oncology nurse-led care management intervention to meet the primary palliative care needs of patients with advanced hematologic malignancies.

study investigators will develop and pilot-test an oncology nurse-led care management intervention to meet the primary palliative care needs of patients with advanced hematologic malignancies. aim 1 is a case series to develop and refine the intervention. during this time, we will develop initial interventionist training materials, study protocols, and a web-based outcomes database; train 2 hematology-oncology nurses; enroll 10 patients with advanced hematologic malignancies and their informal caregivers to receive intervention visits; conduct debriefing interviews; iteratively refine the intervention based on nurse, oncologist, patient, and caregiver feedback; and prepare the protocol for aim 2. aim 2 is a pilot study to assess the feasibility and acceptability of administering the intervention and assessing outcomes. we will recruit 30 patients and their informal caregivers to receive the intervention developed in aim 1 and collect measures of quality of life, symptom burden, anxiety and depressive symptoms, caregiver burden, and healthcare utilization at baseline and monthly for up to three months. trial outcomes will include: rates of enrollment, study completion, and outcome completion; intervention fidelity; and self-reported measures of study burdensomeness and effectiveness among patients, caregivers, and clinicians.

Eligibility criteria:
participants will be (1) patients with advanced hematologic malignancies receiving care at a participating clinic; (2) their caregivers; (3) participating clinicians. patient: inclusion criteria: * adults (≥ 21 years old) * refractory or recurrent hematologic cancer: lymphoma, leukemia, myeloma, amyloidosis (secondary manifestation myeloma \& al amyloidosis), and cml (cml can only be accelerated or blast phase) * planning to receive ongoing care from a participating oncologist and willing to be seen at least monthly. exclusion criteria: * chronic myeloid leukemia (cml) other than accelerated or blast phase * unable to read and respond to questions in english * lacks decision-making capacity, as determined by the patient's oncologist * unable to complete baseline interview caregiver inclusion criteria: * adults (≥ 21 years old) * family member or friend of an eligible patient exclusion criteria: * unable to read and respond to questions in english * unable to complete the baseline interview (patients will be asked to select as caregiver the person who is most likely to accompany them to visits or help with their care should they need it) eligible clinicians will be oncology nurses and oncologists practicing at participating clinics.
progesterone and doppler in recurrent abortion

Conditions: Abortion in First Trimester

Summary: recurrent pregnancy loss is classically defined as the occurrence of three or more consecutive pregnancy loss. the american society of reproductive medicine has recently redefined recurrent pregnancy loss as two or more pregnancy losses. a pregnancy loss is defined as a clinically-recognized pregnancy means that the pregnancy has been visualized on an ultrasound or that pregnancy tissue was identified after a pregnancy loss.

spontaneous pregnancy loss is a surprisingly common occurrence. whereas approximately 15% of all clinically recognized pregnancies result in spontaneous loss, there are many more pregnancies that fail prior to being clinically recognized. only 30% of all conceptions result in a live birth. although no reliable published data have estimated the probability of finding an etiology for recurrent pregnancy loss in a population with 2 versus 3 or more miscarriages, the best available data suggest that the risk of miscarriage in subsequent pregnancies is 30% after 2 losses, compared with 33% after 3 losses among patients without a history of a live birth. this strongly suggests a role for evaluation after just 2 losses in patients with no prior live births. an earlier evaluation may be further indicated if fetal cardiac activity was identified prior to a loss .

Eligibility criteria:
inclusion criteria: 1. pregnant 7-12 weeks documented by pregnancy test \&/or ultrasaound. 2. history of at least 2 prior spontaneous abortion before 12 weeks of gestation. 3. age: 18-35 years 4. willing and able to give informed consent. 5. rh +ve patient 6. bmi: 18-32 7. viable pregnancy through the detection of fetal pulsations by ultrasound 8. singleton pregnancy 9. apparently stable pregnancy (no history of vaginal bleeding in this current pregnancy or signs of sac separation in ultrasound) exclusion criteria: 1. patients diagnosed to have anti-phospholipid syndrome or another recognised thrombophilic or autoimmune conditions. 2. pregnant \> 12 weeks. 3. contraindication to progesterone use. 4. diabetic patients, have glucose intolerance. 5. multiple pregnancies. 6. thyroid disorder
immunonutrition supplementation for improved burn wound healing in older adults

Conditions: Burn Wound

Summary: this pilot study aims to assess the feasibility of providing immunonutrition supplementation to older burn patients (age 55 and older) and its impact on burn wound healing. supplements containing arginine and omega 3 fatty acids have been shown to have beneficial effects on healing in other types of wounds but data within the burn population remains limited. 20 participants will be randomized into two arms, immunonutrition or conventional supplement and can expect to be on study for 3 months.

studies performed previously in burn patients have had mixed patient cohorts with small sample sizes and these have failed to show any large improvements in wound healing. however, in older populations the investigators suspect that immunonutrition supplements may have a larger benefit to these patients as they often present with malnutrition and are more likely to struggle with delayed wound healing. in this pilot study, the investigators look to assess the impact of immunonutrition supplements the burn wound healing of adults over the age of 55 years with 1-15% total burn surface area (tbsa) partial thickness and full thickness burn injuries. the primary outcome objective of the study will be time to complete wound closure. the secondary objectives include need for surgical grafting, length of inpatient stay, and infections including pneumonia, urinary tract infections, wound infections, and blood stream infections.

Eligibility criteria:
inclusion criteria: * subject has partial of full thickness thermal injury of 1-15% of total body surface area (tbsa) * subject has an inpatient admission for their burn * subject or authorized decision maker understands the study procedures and can provide informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator exclusion criteria: * subject with inhalation injury and/or intubation * subject receiving immunosuppressive medications including chronic steroids, immune modulating medications, and chemotherapy prior to admission * subject with pre-existing severe chronic liver disease or end stage renal disease

Keywords: immunonutrition
prevalence and pathological features of c3 dominant glomerulonephritis among egyptian population

Conditions: C3 Nephropathy

Summary: a classification has introduced c3 glomerulopathy (c3 glomerulopathy consensus report) that should be used to designate a disease process due to abnormal control of complement activation, deposition, or degradation and characterized by predominant glomerular c3 fragment deposits with em dense deposits. also, the consensus suggested that the term glomerulonephritis with dominant c3 should be used in practice as a morphological term for those cases with dominant c3 (c3c satining) which is defined as c3 intensity ≥ 2 orders of magnitude more than any other immune reactant on a scale of 0 to 3. c3 glomerulonephritis with 3 dominant c3 deposits include c3 glomerulopathy, post-infectious glomerulonephritis (pign) and others such as para-protein associated glomerulonephritis. in c3 glomerulopathy; the alternative pathway plays a major role in pathogenesis of this group of diseases. it occurs because of dysregulation of alternative complement pathway. dysregulation can be due to mutations of complement proteins or to autoantibodies that promote complement activation. classical/lectin complement pathway has shown potential in evaluation of c3 glomerulopathy. it's suggested that presence of glomerular c4d which is a product of early classical/lectin pathway, should not exclude a c3 glomerulopathy. another disease group with prominent c3 deposits is postinfectious glomerulonephritis (pign) and although pign has traditionally been thought of as a disease triggered by glomerular immune complex deposition but c3 deposition in absence of immune complex deposits can be seen in patients with pign but with the emergence of c3 glomerulonephritis (c3gn), the distinction is difficult as the clinical and pathological presentation may be similar. however, their treatment and clinical course vary significantly. in addition there is overlap between pign and c3 glomerulopathy as they may both show prominent sub-epithelial humps on electron microscopy. this overlap means that it may be very difficult to decide on morphology alone whether a biopsy is a typical pign that will resolve, or whether it represents a c3 glomerulopathy due to an underlying complement abnormality that will lead to persistent glomerulonephritis.


Eligibility criteria:
inclusion criteria: 1. adequate sample with at least 10 glomeruli 2. enough residual tissues in the paraffin blocks 3. available clinical data exclusion criteria: other glomerular diseases such as lupus nephritis, iga nephropathy, membranous glomerulonephritis and immune complex-mediated membranoproliferative gn. cases of minimal change were also excluded.
day of embryo transfer for patients undergoing in vitro fertilization

Conditions: Infertility

Summary: we are examining whether pregnancy rates differ based on day of embryo transfer in patients who replace all available embryos after an in vitro fertilization (ivf) cycle. patients must be undergoing ivf treatment at stanford university and patients will not receive compensation for their participation (no medical costs covered or patient payment for participation).

the decision on the number of embryos to transfer after an ivf cycle is based on the number of available embryos, the quality of the embryos, the patient's age, and the goal of limiting multiple gestations. stanford fertility center and most ivf centers examine the embryos on the third day after oocyte (egg) retrieval to select for the best quality embryos to transfer, and depending on quality, the remaining embryos are frozen to be used in the future. patients with a limited number of embryos, those that plan to replace all available embryos after an ivf cycle, do not need to wait until the third day after oocyte retrieval to select embryos, and may replace the embryos on the second day after the oocyte retrieval. we are examining whether pregnancy rates differ among these patients based on the day of embryo transfer (day 2 vs. day3). patients must be undergoing ivf treatment at stanford university and patients will not receive compensation for their participation (no medical costs covered or patient payment for participation).

Eligibility criteria:
inclusion criteria: patients undergoing fresh ivf cycle at stanford fertility center who plan on replacing all available embryos. exclusion criteria: patients that do not meet above criteria.
postoperative pain of rotary versus reciprocating motions of two single files

Conditions: Postoperative Pain

Summary: an equivalent parallel randomized clinical trial was approved by the local university committee of ethics. 260 children with necrotic primary molars were allocated into 2 equal groups (82 children per group). the participants were allocated into two groups; group "1" teeth were instrumented with oneshape rotary system (micro mega, besancon, france), and group "2" teeth were instrumented with waveone gold reciprocating system (dentsply maillefer, ballaigues, switzerland). postoperative pain was assessed using a four-point pain intensity rating scale adopted from wong-baker faces (wbf) pain scale . the face scale consists of four faces with a brief title describing each face representing a scale from the first face (score 1), second face (score 2), third face (score 3), and forth face (score 4) 3. postoperative pain was assessed at 6 six time intervals (at 6, 12, 24, 48, 72 hours and one-week).


Eligibility criteria:
inclusion criteria: 1. children ages from 4 to 8 years classified as class i or ii according to the american society of anesthesiologists (asa). 2. no previous dental experience. 3. non-vital primary molar (necrotic or with chronic apical periodontitis) which confirmed radiographicly with the presence or absence of periapical radiolucency. 4. severe tooth mobility. exclusion criteria: 1. severe behaviour or emotional disabilities. 2. analgesic intake in the preceding 12 hours. 3. non-restorable crowns of primary molars. 4. radiographic presence of internal root resorption or massive bone destruction. 5. root resorption exceeded one-third of the root length. -
use of anticoagulant, and associated factors of anticoagulant refusal atrial fibrillation patients

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with af and is widely recommended in optimizing af management.direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention. however, the previous study finding highlighted a great gap between current guidelines and the clinical management of af .nonetheless, the decision for anticoagulant use is not straightforward.it is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.


Eligibility criteria:
inclusion criteria: * diagnosis as atrial fibrillation * aged ≧18 years * able to given consent exclusion criteria: * unable/unwillingness to sign informed consent to study * mechanical heart valve * moderate-to-severe mitral stenosis * transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm) * pregnancy * hospitalization within 1 month prior to inclusion in the study.

Keywords: anticoagulants
coviddb: the covid-19 inpatient database

Conditions: COVID-19

Summary: the aim of the project is to better understand the covid-19 inpatient course of the disease and to quickly identify the positive experiences in the treatment in order to update guidelines for the treatment and use of medication.

the exponentially increasing number of sars-cov-2 infected people, despite the influence of the currently existing non-medical measures, is generating a rapidly increasing number of inpatients, some of whom need artificial ventilation. the average focus is on the extent to which the hospitals' capacities will be sufficient to adequately treat all patients. regardless of this, it can be expected that even if the non-medical measures are successful, the number of inpatients treated will remain high in the course of the pandemic. with regard to the distribution of infection, it can be expected that clinics with a wide range of expertise will have to treat a large number of covid-19 patients. so far, however, there is little to no experience in treating patients. in addition to epidemiological data, only case descriptions and some chinese studies mostly from wuhan based on fewer patients are available. in view of the rapidly spreading pandemic, preprints are increasingly being used. what has been missing so far is a uniform, structured recording of the courses of covid-19 inpatients handled by many clinics, which goes beyond the epidemiological events in terms of depth of detail. with this documentation of real processes, the basis for a large number of studies and the associated better understanding of the disease process could be created. the current dynamics make it imperative that the clinics, even those who have not received the most up-to-date scientific knowledge, cannot wait for the results of studies, but rather need concrete help in the treatment of patients. efficient assistance within the framework of a close exchange between the treatment units is only possible with a multicentre, uniform documentation environment. the aim of the project is to better understand the covid-19 inpatient course of the disease and to quickly identify the positive experiences in the treatment in order to update guidelines for the treatment and use of medication.

Eligibility criteria:
inclusion criteria: * covid-19 inpatients exclusion criteria: * assumed covid-19 patient

Keywords: sars-cov-2 covid-19 antiviral therapy ventilation ecmo
pilot study of ensifentrine or placebo delivered via pmdi in hospitalized patients with covid-19

Conditions: Coronavirus Infection; Covid-19; SARS-CoV-2

Summary: this pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pmdi compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to covid-19 infection.

expploratory endpoint, pilot study, not statistically powered go to protocol

Eligibility criteria:
inclusion criteria: * capable of giving informed consent indicating that they understand the purpose of the study and study procedures and agree to comply with the requirements and restrictions listed in the informed consent form and in this protocol. * patient must be at least 18 years of age and less than or equal to 80 years of age at the time of informed consent. * males are eligible to participate or females of non-childbearing potential or wocbp who have a negative pregnancy test at screening are eligible to participate. wocbp and female partners of male participants agree to either abstinence or use at least one primary form of highly effective contraception not including hormonal contraception from the time of screening through day 60 following the first dose of study medication. * clinical status consistent with 3, 4 or 5 on the ordinal scale: hospitalized, not requiring supplemental oxygen; hospitalized, requiring any supplemental oxygen; hospitalized, requiring non-invasive ventilation or use of high flow oxygen devices. * admission to hospital and have a confirmed diagnosis of severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test and displays at least one of the following: respiratory rate \> 24 breaths per minute; new cough; new atypical chest pain; new dyspnea; oxygen saturation \< 97% at rest; chest x-ray with new changes consistent with covid-related airspace disease. * capable of complying with all study restrictions and procedures including ability to use the pmdi correctly. exclusion criteria: * participation in any other clinical trial of an experimental treatment for covid-19, unless related to an expanded access program as part of standard of care at screening or during study. * evidence of multiorgan failure. * requiring mechanical ventilation at screening. * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 x upper limit of normal (uln) at screening. * creatinine clearance \< 30 ml/min at screening. * pregnancy or lactation at screening. * allergy or other contraindication or one of ensifentrine. * in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. * use of prohibited medications (theophylline, pde4 inhibitors \[e.g. roflumilast, apremilast, crisaborole\] within 48 hours of screening or during study) * any other reason that the investigator considers makes the patient unsuitable to participate.